Abstract:Background PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there was no robust evidence showing a PD-L1 inhibitor combined with chemotherapy benefited patients with squamous and non-squamous NSCLC. GEMSTONE-302 aimed to evaluate the efficacy and safety of a PD-L1 inhibitor, sugemalimab, plus chemotherapy for patients with metastatic squamous or non-squamous NSCLC. Methods This randomised, double-blind, phase 3 trial was done in 35 hospitals and academic research centres in China. Eligible patients were aged 18-75 years, had histologically or cytologically confirmed stage IV squamous or non-squamous NSCLC without known EGFR sensitising mutations, ALK, ROS1, or RET fusions, no previous systemic treatment for metastatic disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were randomly assigned (2:1) to receive sugemalimab (1200 mg, intravenously, every 3 weeks) plus platinum-based chemotherapy (carboplatin [area under the curve (AUC) S mg/mL per min, intravenously] and paclitaxel [175 mg/m(2), intravenously] for squamous NSCLC, or carboplatin [AUC S mg/mL per min, intravenously] and pemetrexed [500 mg/m(2), intravenously] for non-squamous NSCLC; sugemalimab group) or placebo plus the same platinum-based chemotherapy regimens for squamous or non-squamous NSCLC as in the sugemalimab group; placebo group) for up to four cycles, followed by maintenance therapy with sugemalimab or placebo for squamous NSCLC, and intravenous sugemalimab 500 mg/m(2) or matching placebo plus pemetrexed for non-squamous NSCLC. Randomisation was done by an interactive voice-web-response system via permuted blocks (block size was a mixture of three and six with a random order within each stratum) and stratified by ECOG performance status, PD-L1 expression, and tumour pathology. The investigators, patients, and the sponsor were masked to treatment assignment. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Safety was analysed in all patients who received at least one treatment dose. Results reported are from a prespecified interim analysis (ie, when the study met the primary endpoint) and an updated analysis (prespecified final analysis for progression-free survival) with a longer follow-up. This study is registered with ClinicalTrials.gov (NCT03789604), is closed to new participants, and follow-up is ongoing. Findings Between Dec 13, 2018, and May 15, 2020, 846 patients were assessed for eligibility; 367 were ineligible, and the remaining 479 patients were randomly assigned to the sugemalimab group (n=320) or placebo group (n=159). At the preplanned interim analysis (data cutoff June 8, 2020; median follow-up 8.6 months [IQR 6.1-11.4]), GEMSTONE-302 met its primary endpoint, with significantly longer progression-free survival in the sugemalimab group compared with the placebo group (median 7.8 months [95% CI 6.9-9.0] vs 4.9 months [4.7-5.0]; stratified hazard ratio [Hit] 0.50 [95% CI 0.39-0.64], p<0.0001]). At the final analysis (March 15, 2021) with a median follow-up of 17.8 months (IQR 15.1-20.9), the improvement in progression-free survival was maintained (median 9.0 months [95% CI 7.4-10.8] vs 4.9 months [4.8-5.1]; stratified HR 0.48 [95% CI 0.39-0.60], p<0.0001). The most common grade 3 or 4 any treatment-related adverse events were neutrophil count decreased (104 p3%1 of 320 with sugemalimab vs 52 [33%] of 159 with placebo), white blood cell count decreased (45 [14%] vs 27 117%1), anaemia (43 113%1 vs 18 [11%]), platelet count decreased (33 [10%] vs 15 [9%]), and neutropenia (12 [4%] vs seven [4%]). Any treatment-related serious adverse events occurred in 73 (23%) patients in the sugemalimab group and 31 (20%) patients in the placebo group. Any treatment-related deaths were reported in ten (3%) patients in the sugemalimab group (pneumonia with respiratory failure in one patient; myelosuppression with septic shock in one patient; pneumonia in two patients; respiratory failure, abdominal pain, cardiac failure, and immune-mediated pneumonitis in one patient each; the other two deaths had an unspecified cause) and in two (1%) patients in the placebo group (pneumonia and multiple organ dysfunction syndrome). Interpretation Sugernalimab plus chemotherapy showed a statistically significant and clinically meaningful progression-free survival improvement compared with placebo plus chemotherapy, in patients with previously untreated squamous and non-squamous metastatic NSCLC, regardless of PD-Li expression, and could be a new first-line treatment option for both squamous and non-squamous metastatic NSCLC. Copyright (C) 2022 Elsevier Ltd. All rights reserved.

A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).

Suvemcitug As Second-Line Treatment of Advanced or Metastatic Solid Tumors and with FOLFIRI for Pretreated Metastatic Colorectal Cancer: Phase Ia/Ib Open Label, Dose-Escalation Trials

Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial

Sugemalimab Versus Placebo, in Combination with Platinum-Based Chemotherapy, As First-Line Treatment of Metastatic Non-Small-cell Lung Cancer (GEMSTONE-302): Interim and Final Analyses of a Double-Blind, Randomised, Phase 3 Clinical Trial.

A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).

A protocol pre-specified interim overall survival analysis of the randomised phase III GEMSTONE-302 trial: sugemalimab or placebo plus platinum-based chemotherapy for first-line metastatic non-small-cell lung cancer

O-4 GEMSTONE-304: A Phase 3 Study of Sugemalimab Plus Chemotherapy Versus Chemotherapy As First-Line Treatment of Patients with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Camrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Oesophageal Squamous Cell Carcinoma: a Single-Arm Phase 2 Trial

First-line Sintilimab Combined with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer: A Phase II Study and Post-Hoc Biomarker Analysis.

Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.

GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).

LBA79 GEMSTONE-303: Prespecified Progression-Free Survival (PFS) and Overall Survival (OS) Final Analyses of a Phase III Study of Sugemalimab Plus Chemotherapy Vs Placebo Plus Chemotherapy in Treatment-Naïve Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Sugemalimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (GEMSTONE-304): a randomized, double-blinded, phase 3 study

Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial

Sugemalimab Versus Placebo after Concurrent or Sequential Chemoradiotherapy in Patients with Locally Advanced, Unresectable, Stage III Non-Small-cell Lung Cancer in China (GEMSTONE-301): Interim Results of a Randomised, Double-Blind, Multicentre, Phase 3 Trial.

A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.

Capecitabine and Oxaliplatin（CAPEOX） Combined with Sintilimab Plus Bevacizumab Biosimilar（ibi305）for First-Line Treatment of Advanced Gastric or Esophagogastric Junction Adenocarcinoma: Study Protocol of a Single-Arm, Phase Ib/II Trial

A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy : The SURPASS Study

Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.

Updated Survival Results of BBCAPX-II: Sintilimab Combined with Bevacizumab and CapeOx As First-Line Treatment in Patients with RAS-mutant, Microsatellite Stable, Unresectable Metastatic Colorectal Cancer.